Navigation Links
Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year

LITTLETON, Mass., Feb. 26 /PRNewswire/ -- Still River Systems announced today the successful operation of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton therapy at a number of hospitals beginning with the first installation at Barnes Jewish Hospital in St. Louis, Missouri this fall.

"The last six months have been very exciting," said Marc Buntaine, CEO. "Still River has achieved all of the component milestones that bring us to system integration and delivery." Proton therapy, widely regarded as the next evolutionary step in the radiation treatment of cancer, has seen unprecedented interest from the radiation oncology and patient communities in recent years. However, the large size and high cost of existing proton therapy systems have made it difficult for the average hospital to add this powerful tool to their cancer fighting arsenal.

The heart of the Monarch250, a superconducting magnet developed in an industrial and academic partnership with the Massachusetts Institute of Technology, has now tested operational and stable at its full design current "This magnet sets a record for magnetic field strength used in a high energy cyclotron. The cyclotron built around this magnet will be the most compact source for proton therapy available today." said Dr. Kenneth Gall, founder and Chief Technology Officer. "All of the Monarch250 sub-systems are now in the final phases of manufacturing and will be ready to ship to our first customers for installation later this year".

Still River's Monarch250 proton therapy system, a unique and compact machine, was developed to provide proton therapy at a greatly reduced cost and size. In addition, Still River Systems has incorporated the latest advancements in radiation therapy patient management with its innovative accelerator technology, including a robotic couch for patient positioning, dedicated proton therapy treatment planning, cone beam CT imaging, and motion management. All of these clinical systems have been integrated within the Monarch250 platform. "Our goal is to provide our customers with a fully integrated, turnkey proton therapy solution with the most advanced clinical systems for patient management" said Dr. Skip Rosenthal, Vice President of Clinical Systems. "Integrating these key radiation therapy technologies is critical to ease of use in a clinical setting."

Still River Systems first installation sites, Barnes Jewish Hospital in St. Louis, Missouri and Robert Wood Johnson University Hospital in New Jersey, have begun construction for the new facilities that will house the first Monarch250 systems in the United States.

Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients' access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. This system has not yet been cleared by the FDA for commercial use in clinical therapy. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit

SOURCE Still River Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
4. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
5. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
6. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
10. Stem Cell Regeneration Repairs Congenital Heart Defect
11. TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration
Post Your Comments:
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):